Novavax said Monday morning that the Food and Drug Administration was asking the company to run a new trial of its Covid-19 ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Analysis found 25% tariff on pharmaceutical imports would hike U.S. drug costs by nearly $51 billion annually, boosting ...

A summary of current health news, including the disbanding of a U.S. Justice Department unit focusing on food and drug safety ...

After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.

Markets were also boosted by the prospect of a quieter geopolitical environment, as the US attempts to smooth the wrinkles in ...

Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration with Biological E. Clinical trials are underway, and the company aims to ...

The FDA, which was supposed to decide by April 1 whether it would approve Novavax's application for a full license, is seeking more clinical studies of the vaccine. Now, because other drugmakers ...